Anxiety and Poor Glycemic Control: A Meta-Analytic Review of the Literature

Anderson, Ryan J.; Grigsby, Allison B.; Freedland, Kenneth E.; Groot, Mary de; McGill, Janet B.; Clouse, Ray E.; Lustman, Patrick J.

doi:10.2190/klgd-4h8d-4ryl-twq8

Cited by 275 publications

(193 citation statements)

References 38 publications

Supporting

Mentioning

184

Contrasting

Unclassified

Order By: Relevance

“…In a study with depressed patients aged 60 and older, venlafaxine was well tolerated. However, undesirable cardiovascular effects occurred in some of the participants (Johnson et al 2006 (Anderson et al 2002) or brain injury (Rogers and Read 2007). An anxiety factor based on four scales measuring psychasthenia, social introversion, phobia, and manifest anxiety independently and prospectively predicted the incidence of myocardial infarction in a study of older men (Shen et al 2008).…”

Section: Treatment Of Patients With Cardiovascular Diseasementioning

confidence: 99%

World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Post-Traumatic Stress Disorders – First Revision

Bandelow

Zohar

Hollander

et al. 2008

The World Journal of Biological Psychiatry

699

410

View full text Add to dashboard Cite

In this report, which is an update of a guideline published in 2002 (Bandelow et al. 2002, recommendations for the pharmacological treatment of anxiety disorder, obsessive-compulsive disorder (OCD) and post-traumatic stress disorder (PTSD) are presented. Since the publication of the first version of this guideline, a substantial number of new randomized controlled studies of anxiolytics have been published. In particular, more relapse prevention studies are now available that show sustained efficacy of anxiolytic drugs. The recommendations, developed by the World Federation of Societies of Biological Psychiatry (WFSBP) Task Force for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Post-Traumatic Stress Disorders, a consensus panel of 30 international experts, are now based on 510 published randomized, placebo-or comparator-controlled clinical studies (RCTs) and 130 open studies and case reports. First-line treatments for these disorders are selective serotonin reuptake inhibitors (SSRIs), serotonin-noradrenaline reuptake inhibitors (SNRIs) and the calcium channel modulator pregabalin. Tricyclic antidepressants (TCAs) are equally effective for some disorders, but many are less well tolerated than the SSRIs/ SNRIs. In treatment-resistant cases, benzodiazepines may be used when the patient does not have a history of substance abuse disorders. Potential treatment options for patients unresponsive to standard treatments are described in this overview. Although these guidelines focus on medications, non-pharmacological were also considered. Cognitive behavioural therapy (CBT) and other variants of behaviour therapy have been sufficiently investigated in controlled studies in patients with anxiety disorders, OCD, and PTSD to support them being recommended either alone or in combination with the above medicines.

show abstract

Section: Treatment Of Patients With Cardiovascular Diseasementioning

confidence: 99%

World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Post-Traumatic Stress Disorders – First Revision

Bandelow

Zohar

Hollander

et al. 2008

The World Journal of Biological Psychiatry

699

410

View full text Add to dashboard Cite

show abstract

“…5 In addition to direct effects on myocardial vulnerability, anxiety may also lead to diabetes, hypertension, and hypercholesterolemia. Chronically elevated catecholamine levels have been shown to increase lipoprotein lipase levels, 23 induce hyperglycemia, 24 and elevate blood pressure. 25 Because these disease states might, at least in part, be biological mediators in the causal pathway of CHD, analyses were performed excluding these variables from the model (multivariable model 1).…”

Section: Albert Et Al Phobic Anxiety and Risk Of Chd And Scd In Womenmentioning

confidence: 99%

Phobic Anxiety and Risk of Coronary Heart Disease and Sudden Cardiac Death Among Women

Albert¹,

Chae²,

Rexrode³

2005

ACC Current Journal Review

View full text Add to dashboard Cite

show abstract

“…It is also well known that T2D patients are more susceptible to anxiety disorders, anxiety symptoms and stress reactivity than individuals without diabetes [3]. Both depression [4] and anxiety [5] have been reported as being associated with poor glycemic control. However, conflicting results have been recently reported about the existence of a significant association between depression or depressive symptoms and poorer glycemic control in both crosssectional and longitudinal studies involving patients with T2D [6,7].…”

Section: Introductionmentioning

confidence: 99%